Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease.

Studies suggest that thrombosis is important in the progression of atherosclerotic lesions. The biochemical markers prothrombin fragment 1-2 and fibrinopeptide A reflect in vivo thrombin generation and activity, respectively. As such, they are markers that might be associated with cardiovascular risk. From the Cardiovascular Health Study, a cohort study of 5201 persons over 65 years of age, 399 persons free of clinical cardiovascular disease (CVD) at the baseline examination were selected for study of specialized markers of hemostasis. We report the cross-sectional relationships of the thrombin markers to CVD risk factors and measures of subclinical CVD. The range of fragment 1-2 2 was 0.12 to 0.85 nmol/L. The range of fibrinopeptide A was 0.9 to 44.1 micrograms/L. High levels of fragment 1-2 and fibrinopeptide A were associated with age, with levels higher in women than men. Fragment 1-2 was associated with smoking; high levels of triglyceride, creatinine, and C-reactive protein; and low levels of glucose. Fibrinopeptide A was associated with high C-reactive protein and apolipoprotein(a) and lower ankle-brachial index. There were no significant associations of the thrombin markers with race, fibrinogen, alcohol consumption, diabetes, or most measures of subclinical CVD. Study findings support a hypothesis that there are physiological interrelationships between cardiac risk factors, hemostasis, inflammation, and progression of atherosclerosis.

[1]  P. Savage,et al.  Association of Fibrinogen and Coagulation Factors Vll and VIII with Cardiovascular Risk Factors in the Elderly The Cardiovascular Health Study , 1996 .

[2]  L. Kuller,et al.  Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. , 1995, Annals of epidemiology.

[3]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[4]  J. Cooper,et al.  The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.

[5]  T. Ortel,et al.  Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. , 1994, Clinical chemistry.

[6]  R. Rauramaa,et al.  Apolipoprotein(a), Fibrinopeptide A and Carotid Atherosclerosis in Middle-Aged Men , 1994, Thrombosis and Haemostasis.

[7]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[8]  M. Pirisi,et al.  Fibrinogen Plasma Levels as a Marker of Thrombin Activation: New Insights on the Role of Fibrinogen as a Cardiovascular Risk Factor , 1994, Thrombosis and Haemostasis.

[9]  G. Assmann,et al.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[10]  V. Fuster,et al.  Atherogenesis and inflammation. , 1993, European heart journal.

[11]  J. Polak,et al.  Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. , 1993, Circulation.

[12]  L. Fried,et al.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[13]  E. Ernst,et al.  Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.

[14]  J. Philippé,et al.  Coagulation system activation and increase of D‐dimer levels in peripheral arterial occlusive disease , 1993, American journal of hematology.

[15]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[16]  A. Stead,et al.  Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. , 1993, Clinical Chemistry.

[17]  M. Tennant,et al.  Lipoprotein(a) and its role in occlusive vascular disease. , 1993, Annals of the Royal College of Surgeons of England.

[18]  Tracy Rp,et al.  Thrombosis and cardiovascular risk in the elderly. , 1992 .

[19]  V. Fuster,et al.  Thrombosis in Cardiovascular Disorders , 1992, Annals of Internal Medicine.

[20]  L. Tavazzi,et al.  The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[21]  S. Hifumi,et al.  Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  P. Savage,et al.  The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study. , 1992, Annals of epidemiology.

[23]  B. Psaty,et al.  Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. , 1992, The American journal of cardiology.

[24]  K. Bauer,et al.  Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease , 1992, Thrombosis and Haemostasis.

[25]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[26]  B. Boneu,et al.  Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. , 1992, Nouvelle revue francaise d'hematologie.

[27]  H. S. Klopfenstein,et al.  Echocardiographic design of a multicenter investigation of free-living elderly subjects: the Cardiovascular Health Study. , 1992, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  B M Psaty,et al.  Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. , 1991, Stroke.

[29]  P C Elwood,et al.  Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.

[30]  W. Stüber,et al.  Determination of Human Prothrombin Activation Fragment 1+2 in Plasma with an Antibody against a Synthetic Peptide , 1991, Thrombosis and Haemostasis.

[31]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[32]  J. Badimón,et al.  Atherosclerotic plaque rupture and thrombosis. Evolving concepts. , 1990, Circulation.

[33]  P. Hass,et al.  A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). , 1990, Clinical chemistry.

[34]  A. Gershlick Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically? , 1990, Circulation.

[35]  J. Owen The Utility of Plasma Fibrinopeptide Assays , 1989, Thrombosis and Haemostasis.

[36]  P. Rentrop,et al.  Impaired Fibrinolytic Capacity and Tissue Plasminogen Activator Release in Patients with Restenosis after Percutaneous Transluminal Coronary Angioplasty (PTCA) , 1989, Thrombosis and Haemostasis.

[37]  P. Fratino,et al.  Fibrinopeptide A levels in patients with acute ischaemic heart disease. , 1989, Haemostasis.

[38]  P. Mombaerts,et al.  Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis , 1987, Thrombosis and Haemostasis.

[39]  P. Vokonas,et al.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. , 1987, The Journal of clinical investigation.

[40]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[41]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[42]  P. Théroux,et al.  Fibrinopeptide A and platelet factor levels in unstable angina pectoris. , 1987, Circulation.

[43]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[44]  A. Jaffe,et al.  Fibrinopeptide A: a marker of acute coronary thrombosis. , 1985, Circulation.

[45]  J. Soria,et al.  Markers of Fibrinogen Derivatives Used in Clinical Investigation , 1985, Seminars in thrombosis and hemostasis.

[46]  Daniel B. Mark,et al.  Acute Coronary Care , 1985, Springer US.

[47]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[48]  S. Frebelius,et al.  Rapid radioimmunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite. , 1980, Thrombosis research.

[49]  J. Hirsh,et al.  Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. , 1978, Blood.

[50]  R. Canfield,et al.  Measurement of fibrinopeptide A in human blood. , 1974, The Journal of clinical investigation.

[51]  E. Simonson,et al.  The Electrocardiogram in Population Studies: A Classification System , 1960, Circulation.